Full Press Release Details
IDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161.
IDYA
IDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161
Key Takeaway: IDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161
Price reaction · baseline $16.84 (2022-12-09 close) · clean, no other IDYA news in the window
day 0 close · peak
+1.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma